Table 4.
Characteristics of patients with fibrosis regression compared to the non-regression or progression group.
| Characteristic | Fibrosis Regression n = 119 (%) |
No Fibrosis Regression n = 90 (%) |
p-Value |
|---|---|---|---|
| Age | 59.4 ± 10.7 | 56.1 ± 11.9 | 0.018 |
| Age at diagnosis | 48.6 ± 11.8 | 44.9 ± 12 | 0.027 |
| Age at treatment | 55.5 ± 10.5 | 52.1 ± 11.4 | 0.029 |
| Sex (male) | 75 (63) | 42 (46.7) | 0.018 |
| Ethnicity | |||
| Jewish | 84 (93.3) | 117 (98.3) | |
| Bedouin | 2 (1.7) | 6 (6.7) | 0.130 |
| Genotype | 0.664 | ||
| 1a | 16 (17.8) | 18 (15.1) | |
| 1b | 54 (60) | 67 (56.3) | |
| 2a | 5 (5.6) | 4 (3.4) | |
| 3 | 13 (14.4) | 25 (21) | |
| 4a | 2 (2.2) | 2 (1.6) | |
| Patient type | 0.984 | ||
| Naïve | 85 (72) | 64 (71.9) | |
| Experienced | 33 (28) | 25 (28.1) | |
| Viral load (IU/mL) | 0.833 | ||
| ≤800,000 | 44 (37) | 32 (35.6) | |
| >800,000 | 75 (63) | 58 (64.4) | |
| Method of fibrosis assessment at treatment time | 0.052 | ||
| Fibrotest | 101 (78.4) | 64 (77.1) | |
| Fibroscan | 10 (8.8) | 11 (13.3) | |
| Fibrosis stage at treatment time | <0.001 | ||
| F0–F1 | 1 (0.8) | 52 (57.8) | |
| F2 | 45 (37.8) | 11 (12.2) | |
| F3 | 33 (27.7) | 5 (5.6) | |
| F4 | 40 (33.6) | 22 (22.4) | |
| Updated fibrosis stage | <0.001 | ||
| F0–F1 | 93 (78) | 53 (59) | |
| F2 | 15 (12.6) | 4 (4.4) | |
| F3 | 11 (9.25) | 5 (5.6) | |
| F4 | 0 | 25 (27.8) | |
| Sustained virologic response (SVR) | 117 (98.3) | 90 (100) | 0.217 |
| Liver cirrhosis | 42 (36.2) | 27 (30.7) | 0.409 |
| HCC | 4 (3.5) | 6 (6.9) | 0.267 |
| Esophageal varices | 9 (7.6) | 15 (16.7) | 0.043 |
| Esophageal varices bleeding | 2 (1.7) | 9 (10) | 0.008 |
| SBP | 0 | 2 (2.2) | 0.104 |
| Child–Pugh classification—at treatment time | 0.650 | ||
| A | 36 (85.7) | 22 (81.5) | |
| B | 6 (84.3) | 5 (18.5) | |
| C | 0 | ||
| Child–Pugh classification—updated | 0.719 | ||
| A | 37 (85.7) | 24 (88.9) | |
| B | 5 (14.3) | 3 (11.1) | |
| C | 0 | 0 |